BioRegenx, Inc. (BRGX)
OTCMKTS
· Delayed Price · Currency is USD
0.0090
0.00 (0.00%)
Apr 27, 2026, 9:30 AM EST
BioRegenx Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Revenue | 1.85 | 2.34 | 3.41 | 0.04 | 3.99 | Upgrade
|
| Revenue Growth (YoY) | -20.75% | -31.40% | 7991.78% | -98.94% | -48.79% | Upgrade
|
| Cost of Revenue | 0.35 | 0.68 | 1.1 | 0.05 | 1.43 | Upgrade
|
| Gross Profit | 1.5 | 1.66 | 2.31 | -0.01 | 2.56 | Upgrade
|
| Selling, General & Admin | 2.02 | 6.03 | 5.72 | 0.06 | 5.81 | Upgrade
|
| Amortization of Goodwill & Intangibles | - | 2.18 | - | 0.01 | - | Upgrade
|
| Operating Expenses | 2.02 | 8.21 | 5.72 | 0.07 | 5.81 | Upgrade
|
| Operating Income | -0.52 | -6.55 | -3.41 | -0.08 | -3.25 | Upgrade
|
| Interest Expense | -0.3 | -0.29 | -0.19 | - | -0.45 | Upgrade
|
| Interest & Investment Income | - | - | - | - | 0.03 | Upgrade
|
| EBT Excluding Unusual Items | -0.82 | -6.84 | -3.6 | -0.08 | -3.67 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | -0.01 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 0 | Upgrade
|
| Asset Writedown | -0.73 | -16.21 | - | - | -1.11 | Upgrade
|
| Other Unusual Items | - | - | - | - | 0.07 | Upgrade
|
| Pretax Income | -1.54 | -23.05 | -3.6 | -0.08 | -4.72 | Upgrade
|
| Net Income | -1.54 | -23.05 | -3.6 | -0.08 | -4.72 | Upgrade
|
| Net Income to Common | -1.54 | -23.05 | -3.6 | -0.08 | -4.72 | Upgrade
|
| Shares Outstanding (Basic) | 960 | 912 | 640 | 270 | 35 | Upgrade
|
| Shares Outstanding (Diluted) | 960 | 912 | 640 | 270 | 35 | Upgrade
|
| Shares Change (YoY) | 5.19% | 42.61% | 137.18% | 664.87% | 1.01% | Upgrade
|
| EPS (Basic) | -0.00 | -0.03 | -0.01 | -0.00 | -0.13 | Upgrade
|
| EPS (Diluted) | -0.00 | -0.03 | -0.01 | -0.00 | -0.13 | Upgrade
|
| Free Cash Flow | 0.03 | -0.51 | -1.52 | -0.06 | -3.96 | Upgrade
|
| Free Cash Flow Per Share | - | -0.00 | -0.00 | - | -0.11 | Upgrade
|
| Gross Margin | 81.08% | 70.87% | 67.76% | -25.52% | 64.13% | Upgrade
|
| Operating Margin | -27.98% | -279.93% | -99.92% | -185.74% | -81.57% | Upgrade
|
| Profit Margin | -83.23% | -985.17% | -105.53% | -185.74% | -118.37% | Upgrade
|
| Free Cash Flow Margin | 1.61% | -21.95% | -44.41% | -153.35% | -99.39% | Upgrade
|
| EBITDA | -0.44 | -4.33 | -3.4 | -0.07 | -3.25 | Upgrade
|
| EBITDA Margin | -23.94% | -185.10% | -99.78% | -174.42% | -81.55% | Upgrade
|
| D&A For EBITDA | 0.08 | 2.22 | 0 | 0 | 0 | Upgrade
|
| EBIT | -0.52 | -6.55 | -3.41 | -0.08 | -3.25 | Upgrade
|
| EBIT Margin | -27.98% | -279.93% | -99.92% | -185.74% | -81.56% | Upgrade
|
| Revenue as Reported | 1.85 | 2.34 | 3.41 | - | - | Upgrade
|
| Advertising Expenses | 0.08 | 0.07 | - | 0.01 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.